Cargando…

Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial

BACKGROUND: Tuberculosis is a growing international health concern. It is the biggest killer among the infectious diseases in the world today. Early detection of drug resistance allows starting of an appropriate treatment. Resistance to drugs is due to particular genomic mutations in specific genes...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelaal, Amina, El-Ghaffar, Hassan Abd, Zaghloul, Mohammad Hosam Eldeen, El mashad, Noha, Badran, Ehab, Fathy, Amal
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654859/
https://www.ncbi.nlm.nih.gov/pubmed/19183459
http://dx.doi.org/10.1186/1476-0711-8-4
_version_ 1782165408569098240
author Abdelaal, Amina
El-Ghaffar, Hassan Abd
Zaghloul, Mohammad Hosam Eldeen
El mashad, Noha
Badran, Ehab
Fathy, Amal
author_facet Abdelaal, Amina
El-Ghaffar, Hassan Abd
Zaghloul, Mohammad Hosam Eldeen
El mashad, Noha
Badran, Ehab
Fathy, Amal
author_sort Abdelaal, Amina
collection PubMed
description BACKGROUND: Tuberculosis is a growing international health concern. It is the biggest killer among the infectious diseases in the world today. Early detection of drug resistance allows starting of an appropriate treatment. Resistance to drugs is due to particular genomic mutations in specific genes of Mycobacterium tuberculosis(MTB). The aim of this study was to identify the presence of Isoniazid (INH) and Rifampicin(RIF) drug resistance in new and previously treated tuberculosis (TB) cases using DNA sequencing. METHODS: This study was carried out on 153 tuberculous patients with positive Bactec 460 culture for acid fast bacilli. RESULTS: Of the 153 patients, 105 (68.6%) were new cases and 48 (31.4%) were previously treated cases. Drug susceptibility testing on Bactec revealed 50 resistant cases for one or more of the first line antituberculous. Genotypic analysis was done only for rifampicin resistant specimens (23 cases) and INH resistant specimens (26 cases) to detect mutations responsible for drug resistance by PCR amplification of rpoB gene for rifampicin resistant cases and KatG gene for isoniazid resistant cases. Finally, DNA sequencing was done for detection of mutation within rpoB and KatG genes. Genotypic analysis of RIF resistant cases revealed that 20/23 cases (86.9%) of RIF resistance were having rpoB gene mutation versus 3 cases (13.1%) having no mutation with a high statistical significant difference between them (P < 0.001). Direct sequencing of Kat G gene revealed point mutation in 24/26 (92.3%) and the remaining 2/26 (7.7%) had wild type KatG i.e. no evidence of mutation with a high statistical significant difference between them (P < 0.001). CONCLUSION: We can conclude that rifampicin resistance could be used as a useful surrogate marker for estimation of multidrug resistance. In addition, Genotypic method was superior to that of the traditional phenotypic method which is time-consuming taking several weeks or longer.
format Text
id pubmed-2654859
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26548592009-03-13 Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial Abdelaal, Amina El-Ghaffar, Hassan Abd Zaghloul, Mohammad Hosam Eldeen El mashad, Noha Badran, Ehab Fathy, Amal Ann Clin Microbiol Antimicrob Research BACKGROUND: Tuberculosis is a growing international health concern. It is the biggest killer among the infectious diseases in the world today. Early detection of drug resistance allows starting of an appropriate treatment. Resistance to drugs is due to particular genomic mutations in specific genes of Mycobacterium tuberculosis(MTB). The aim of this study was to identify the presence of Isoniazid (INH) and Rifampicin(RIF) drug resistance in new and previously treated tuberculosis (TB) cases using DNA sequencing. METHODS: This study was carried out on 153 tuberculous patients with positive Bactec 460 culture for acid fast bacilli. RESULTS: Of the 153 patients, 105 (68.6%) were new cases and 48 (31.4%) were previously treated cases. Drug susceptibility testing on Bactec revealed 50 resistant cases for one or more of the first line antituberculous. Genotypic analysis was done only for rifampicin resistant specimens (23 cases) and INH resistant specimens (26 cases) to detect mutations responsible for drug resistance by PCR amplification of rpoB gene for rifampicin resistant cases and KatG gene for isoniazid resistant cases. Finally, DNA sequencing was done for detection of mutation within rpoB and KatG genes. Genotypic analysis of RIF resistant cases revealed that 20/23 cases (86.9%) of RIF resistance were having rpoB gene mutation versus 3 cases (13.1%) having no mutation with a high statistical significant difference between them (P < 0.001). Direct sequencing of Kat G gene revealed point mutation in 24/26 (92.3%) and the remaining 2/26 (7.7%) had wild type KatG i.e. no evidence of mutation with a high statistical significant difference between them (P < 0.001). CONCLUSION: We can conclude that rifampicin resistance could be used as a useful surrogate marker for estimation of multidrug resistance. In addition, Genotypic method was superior to that of the traditional phenotypic method which is time-consuming taking several weeks or longer. BioMed Central 2009-01-30 /pmc/articles/PMC2654859/ /pubmed/19183459 http://dx.doi.org/10.1186/1476-0711-8-4 Text en Copyright © 2009 Abdelaal et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Abdelaal, Amina
El-Ghaffar, Hassan Abd
Zaghloul, Mohammad Hosam Eldeen
El mashad, Noha
Badran, Ehab
Fathy, Amal
Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial
title Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial
title_full Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial
title_fullStr Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial
title_full_unstemmed Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial
title_short Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial
title_sort genotypic detection of rifampicin and isoniazid resistant mycobacterium tuberculosis strains by dna sequencing: a randomized trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654859/
https://www.ncbi.nlm.nih.gov/pubmed/19183459
http://dx.doi.org/10.1186/1476-0711-8-4
work_keys_str_mv AT abdelaalamina genotypicdetectionofrifampicinandisoniazidresistantmycobacteriumtuberculosisstrainsbydnasequencingarandomizedtrial
AT elghaffarhassanabd genotypicdetectionofrifampicinandisoniazidresistantmycobacteriumtuberculosisstrainsbydnasequencingarandomizedtrial
AT zaghloulmohammadhosameldeen genotypicdetectionofrifampicinandisoniazidresistantmycobacteriumtuberculosisstrainsbydnasequencingarandomizedtrial
AT elmashadnoha genotypicdetectionofrifampicinandisoniazidresistantmycobacteriumtuberculosisstrainsbydnasequencingarandomizedtrial
AT badranehab genotypicdetectionofrifampicinandisoniazidresistantmycobacteriumtuberculosisstrainsbydnasequencingarandomizedtrial
AT fathyamal genotypicdetectionofrifampicinandisoniazidresistantmycobacteriumtuberculosisstrainsbydnasequencingarandomizedtrial